HUmira treatment in PSoriatic Arthritis (HUPSA) - a danish multicenter study of new imaging- and bio-markers for improved assessment of disease activity and progression and prediction of therapeutic outcome in patients with psoriatic arthritis receiving Humira. - HUPSA

Active, not recruiting

• Conditions: Psoriatic Arthritis according to the Moll and Wright diagnostic criteria.

• Registration Number: EUCTR2006-000004-16-DK
• Lead Sponsor: Hvidovre Hospital, Dept. of Rheumatology

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-02-21
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1.Diagnosis of PsA according to Moll and Wright diagnostic criteria.
2.Clinical active disease, defined as ³3 (of 76) swollen joints and ³ 3 (of 78) tender joints.
3.Involvement of the hands (Clinical swelling of ³ 1 finger joint and/or ³1 sausage finger).
4.Clinical indication for anti-TNFa therapy, according to treating physician.
5.Adequate birth control.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1.Pregnant or breast-feeding women.
2.No prior anti-TNFa-therapy.
3.No treatment with other DMARDs than MTX later than 4 weeks before inclusion.
4.No steroids later than 4 weeks before inclusion.
5.No contraindikations for MRI.
6.No other significant dermatological disorder tha psoriasis.
7.No PUVA treatment or other UVA treatment later than 2 weeks before inclusion.
8.No contraindications for anti-TNFa-therapy.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified